International Conference on Pharmaceutical Testing and Adverse Effects

From Verify.Wiki
Jump to: navigation, search
International Conference on Pharmaceutical Testing and Adverse Effects
Date 2016-08-08
Place Seattle

The ICPTAE 2016

18th International Conference on Pharmaceutical Testing and Adverse Effects aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results about all aspects of Pharmaceutical Testing and Adverse Effects. It also provides the premier interdisciplinary forum for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns, practical challenges encountered and the solutions adopted in the field of Pharmaceutical Testing and Adverse Effects

Top Photos

Top Videos

Speaker Highlights

Treatment Satisfaction and Safety of Sitagliptin versus Pioglitazone in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Monotherapy Dr. Shahnaz Haque

"Diabetes Mellitus" is a chronic metabolic disease affecting millions worldwide. Metformin is the most commonly prescribed first line oral hypoglycemic drug for type 2 diabetes mellitus, but due to progressive worsening of blood glucose control during the natural history of type 2 diabetes, combination therapy usually becomes necessary. Objective: This study was designed to assess the treatment satisfaction between Sitagliptin versus Pioglitazone added to Metformin in patients with type 2 diabetes mellitus (T2DM). Methods: We conducted a prospective, open label, randomized, parallel group study in SIMS, Hapur, U.P. Eligible patients fulfilling inclusion criteria were randomized into two groups having 25 patients in each group using tab Sitagliptin 100mg, tab Pioglitazone 30mg added to ongoing tab Metformin (500mg) therapy for 16 weeks. The follow-up visits were on weeks 4,12 and 16. Result: 16 weeks later, addition of Sitagliptin 100mg compared to that of Pioglitazone 30 mg to ongoing Metformin therapy provided similar glycosylated hemoglobin (HbA1c) lowering efficacy in patients with T2DM with inadequate glycemic control on metformin monotherapy. Change in HbA1c in group1 was -0.656±0.21%(p<0.0001) whereas in group2 was -0.748±0.35%(p<0.0001). Hence decrease in HbA1c from baseline was more in group2. Both treatments were well tolerated with negligible risk of hypoglycaemia. Weight loss was observed with Sitagliptin in contrast to weight gain seen in Pioglitazone. Conclusion: In this study, Sitagliptin 100 mg along with metformin therapy in comparison to pioglitazone 30 mg plus metformin therapy was both effective, well-tolerated and improved glycemic control in both the groups. Addition of pioglitazone had cause oedema and weight gain to the patients whereas sitagliptin caused weight loss in its patients.[1]


Bio-pharmaceutics and pharmaceutics Prevention of adverse effects Pharmacy practice Pharmaceutical testing Pharmaceutical chemistry Pharmaceutical crops Pharmacology and antibiotics Drug discovery and development Protein-protein interactions as drug targets Adrenergic drugs Anesthesia pharmacology Application of membrane protein structure determination and its applications in drug design Chemotherapy and other anti-neoplastic drugs Clinical pharmacology and pharmacy Design and optimization of dosage regimens Drug development Drug metabolism and interactions

The target audiences for these conferences are: Pharmacovigilance Students, Scientists Pharmacovigilance Researchers Pharmacovigilance Faculty Medical Colleges Pharmacovigilance Associations and Societies Business Entrepreneurs Training Institutes Software Developing Companies Manufacturing Medical Devices Companies Data Management Companies

Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.

Pharmacovigilance Market, by Phases of Drug Development:

Preclinical Studies

Phase I

Phase II

Phase III

Phase IV or Post Marketing Surveillance

Pharmacovigilance Market, by Type of Methods:

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Cohort Event Monitoring

EHR Mining

Pharmacovigilance Market, by Type of Service:

In-House Contract Outsourcing [1]

Conference Highlights

Drug Safety Adverse Drug Reactions Pharmacovigilance Significance & Scope Good Pharmacovigilance Practice Pharmacovigilance and Risk Management Pharmacokinetics and Pharmacodynamics Pre-Clinical and Clinical Trials Clinical Trials on Various Disorders Diversity in Industrial Clinical Trials and Clinical Research Clinical Research and Statistics Case Report in Clinical Trial Data Quality Management and Analysis PV Data Base Managemaent PV Consultings And Bussiness Opportunity Regulatory Affairs Growth Strategies in Pharma Pharmacy Practices and its Challenges Entrepreneurs Investment Meet <>

Top Quotes

Fun things happened


Conference Papers


Verification history